Indo Borax & Chemicals Limited has made the audio recording of its first-quarter fiscal year 2027 earnings call available to investors and analysts. The discussion covered the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026.

Earnings Call Details

The company held the conference call on Wednesday, September 2, 2026, at 4:00 pm. This disclosure follows a previous intimation sent on September 1, 2026, regarding the schedule for the event.

The audio recording is accessible via the company’s official website. The link provides direct access to the full transcript of the management’s discussion on quarterly performance.

Regulatory Compliance

This release is issued pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pravin Prabhakar Chavan, Company Secretary and Compliance Officer, signed the communication addressed to the BSE Limited and National Stock Exchange of India Limited.

Indo Borax & Chemicals Ltd indo borax & chemicals reported a 59.31% year-on-year increase in consolidated net profit to ₹16.25 crore for the quarter ended June 30, 2026. The specialty chemicals manufacturer also saw its revenue jump 31.34% to ₹70.36 crore, supported by improved capacity utilization and better realizations.

The company’s earnings per share (EPS) stood at ₹5.07 for the period, up from ₹3.20 in Q1FY26. Management attributed the strong performance to steady domestic demand and operational efficiencies across its Pithampur facility in Madhya Pradesh.

Financial Performance

Consolidated operating revenue expanded significantly compared to the previous quarter and fiscal year period. EBITDA rose sharply, reflecting improved margin dynamics.

For the full FY26, the company logged a revenue of ₹215.45 crore, a 22.9% increase over FY25’s ₹175.26 crore. Full-year net profit grew 18.3% to ₹50.27 crore, with an EPS of ₹15.67. Despite the revenue growth, full-year EBITDA contracted slightly to ₹44.16 crore from ₹45.89 crore in FY25, maintaining a healthy margin of 20.5%.

What the Numbers Show

The divergence between quarterly and annual profitability metrics highlights significant improvement in recent months. While full-year FY26 EBITDA declined marginally despite substantial revenue growth, Q1FY27 EBITDA surged 62.16% to ₹19.80 crore. This suggests that the operational efficiencies and better realizations cited by management have had a pronounced impact in the current quarter, reversing the slight margin pressure seen during the broader fiscal year.

Strategic Developments

Post-quarter, the Board of Directors approved two major strategic moves:

• Amalgamation: The company will amalgamate its wholly owned subsidiary, Indoborax Infrastructure Private Limited, to streamline governance and enhance resource utilization.
• Acquisition: Indo Borax approved the acquisition of 64.26% equity shares of Kronox Lab Sciences for an aggregate consideration of ₹246.12 crore. The deal includes an open offer for up to 25.79% additional stake. Kronox, which reported FY26 revenue of ₹101 crore and PAT of ~₹28 crore, brings 185+ specialty chemical products and export presence to the group.

Managing Director Suresh Kalra stated that the acquisition aims to leverage Kronox’s experience to fortify margins through synergies. The company remains debt-free and continues to focus on expanding its boric acid and Disodium Octaborate Tetrahydrate (DOT) portfolio, targeting incremental domestic demand in steel, ceramics, and agriculture sectors.